ATIM-28. PHASE 2 STUDY OF ERC1671 PLUS BEVACIZUMAB VS BEVACIZUMAB PLUS PLACEBO IN RECURRENT GBM INTERIM RESULTS AND CORRELATIONS WITH CD4+ T LYMPHOCYTE COUNTS

ABSTRACT: Abstract

BACKGROUND

ERC1671 is an allogeneic/autologous therapeutic glioblastoma (GBM) vaccine composed of whole, inactivated tumor cells mixed with tumor cell lysates derived from the patient and three GBM donors. Previously published compassionate use data showed an overall survival (OS) of 43 weeks (10 months) in patients with a good performance status.

METHODS

In this double-blinded, randomized, phase 2 study bevacizumab-naïve patients with recurrent GBM were randomized after surgery to receive either ERC1671 in combination with GM-CSF and cyclophosphamide plus bevacizumab, or placebo plus bevacizumab. The trial is registered with ClinicalTrials.gov (NCT01903330). Interim

RESULTS

Nine patients, with a KPS 70, were randomized and treated. At the time of furthe

SUBMITTER: Bota D 

PROVIDER: S-EPMC6216140 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature